Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

March 27, 2024

https://www.globenewswire.com/news-release/2024/03/27/2853131/0/en/Aeterna-Zentaris-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Announces-Completion-of-Enrollment-in-Ongoing-Pivotal-DETECT-Trial-for-the-Diagnosis-of-Childhood-O.html

– Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial

– Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.